The cardiovascular actions of omapatrilat in spontaneously hypertensive rats

Current Hypertension Reports

Volumn 3, Issue SUPPL. 2, 2001, Pages

  Dong, Yafeng ^a   Zhou, Hui ^a   Shaffer, Eric ^a   Atamas, Nickolai ^a   Liao, Wei Chi ^a   Wei, Chiming ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FOSINOPRIL; OMAPATRILAT; PYRIDINE DERIVATIVE; THIAZEPINE DERIVATIVE;

ANIMAL; ARTICLE; BLOOD PRESSURE; COMPARATIVE STUDY; DRUG EFFECT; ENDOCARDIUM; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEMODYNAMICS; HYPERTENSION; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR AGENTS; ENDOCARDIUM; FOSINOPRIL; HEMODYNAMIC PROCESSES; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; PYRIDINES; RATS; RATS, INBRED SHR; THIAZEPINES; VENTRICULAR FUNCTION, LEFT;

EID: 0035650677     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-001-0100-0     Document Type: Article

References (18)

1. Packer M: Drugs for heart failure that interfere with the renin-angiotensin system. In Heart Failure: Scientific Principles and Clinical Practice. Edited by Poole-Wilson PA, Colucci WS, Massie BM, Chatterjee K, Coats AJS: New York: Churchill Livingstone; 1997:687-690.
2. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 1997, 157:2413-2446.
3. Robl JA, Trippodo NC, Petrillo EW: Neutral endopeptidase inhibitors and combined inhibitors of neutral endopeptidase and angiotensin-converting enzyme. In Antihypertensive Drugs. Edited by van Zwieten PA, Greenlee WJ. Australia: Harwood Academic Publishers; 1997:113-211.
4. Richards AM, Wittert GA, Crozier IG, et al.: Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. J Hypertens 1993, 11:407-416. (Pubitemid 23139783)
5. Burnett JC Jr: Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens 1999, 17:S37-S43.
6. Weber M: Emerging treatments for hypertension: potential role for vasopeptidase inhibition. Am J Hypertens 1999, 12:139S-147S.
7. Trippodo NC, Robl JA, Asaad MM, et al.: Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens 1998, 11:363-372. (Pubitemid 28186749)
8. Thomas CV, McDaniel GM, Holzgrefe HH, et al.: Chronic dual inhibition of angiotensin-converting enzyme and neutral endopeptidase during the development of left ventricular dysfunction in dogs. J Cardiovasc Pharmacol 1998, 32:902-912. (Pubitemid 28563912)
9. Bunag RD, Butterfield J: Tail-cuff blood pressure measurement without external preheating in awake rats. Hypertension 1982, 4:898-903. (Pubitemid 13176958)
10. Shorofsky SR, Aggarwal R, Corretti M, et al.: Cellular mechanisms of altered contractility in the hypertrophied heart. Big heart, big sparks. Circ Res 1999, 84:424-434. (Pubitemid 29120008)
11. Schiller NB, Shah PM, Crawford M, et al.: Recommendations for quantification of the left ventricle by 2D echocardiography: American Society of Echocardiography Committee on Standards Subcommittee. J Am Soc Echo 1989, 2:358-367.
12. Bevan EG, Connell JMC, Doyle J, et al.: Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. J Hypertens 1992, 10:607-613.
13. Massien C, Azizi M, Guyene T-T, et al.: Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans. Clin Pharmacol Ther 1999, 65:448-459. (Pubitemid 29196549)
14. Raut R, Rouleau J-L, Blais C Jr, et al.: Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11. Am J Physiol 1999, 276:H1769-H1779. (Pubitemid 29246565)
15. Interngan HD, Schiffrin EL: Vasopeptidase inhibition has potent effects on blood pressure and resistance arteries in stroke-prone spontaneously hypertensive rats. Hypertension 2000, 35:1221-1225. (Pubitemid 30413654)
16. Trippodo NC, Fox M, Monticello TM, et al.: Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharmacol 1999, 34:782-790.
17. Weinberg EO, Schoen FJ, George D, et al.: Angiotensin converting enzyme inhibition prolongs survival and modifies the transition to heart failure in rats with pressure overload hypertrophy due to ascending aortic stenosis. Circulation 1994, 90:1410-1422. (Pubitemid 24284463)
18. Rouleau JL, Pfeffer MA, Stewart DJ, et al.: Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000, 356:615-620. (Pubitemid 30627587)